A preclinical model to assess the antigenicity of an HLA-A2 melanoma cell vaccine
Article first published online: 28 JUN 2006
Copyright © 1993 American Cancer Society
Volume 72, Issue 3, pages 750–759, 1 August 1993
How to Cite
Hayashi, Y., Hoon, D. S. B., Foshag, L. J., Park, M. S., Terasaki, P. I. and Morton, D. L. (1993), A preclinical model to assess the antigenicity of an HLA-A2 melanoma cell vaccine. Cancer, 72: 750–759. doi: 10.1002/1097-0142(19930801)72:3<750::AID-CNCR2820720319>3.0.CO;2-V
- Issue published online: 28 JUN 2006
- Article first published online: 28 JUN 2006
- Manuscript Accepted: 22 MAR 1993
- National Cancer Institute. Grant Number: CA 12582
- Joseph Drown Foundation
- tumor vaccine;
- cytotoxic T-cell
Background. The authors have demonstrated that immunization with melanoma whole-cell vaccine (MCV) augments T-cell responses to melanoma and that cytotoxic T-cells (CTL) recognize allogeneic melanoma-bearing shared HLA-A antigens. A preclinical model was developed to assess CTL activation in vitro using melanoma lines as stimulators. HLA-A2 expression is predominant in melanoma patients and plays a role in HLA class I restricted CTL killing of melanomas. The authors hypothesized that a MCV consisting of allogeneic HLA-A2 melanomas may be as good as autologous melanoma MCV for HLA-A2 patients.
Methods. CTL were generated from peripheral blood lymphocytes of patients with HLA-A2 melanoma by stimulation with autologous melanoma, allogeneic melanoma (HLA-A2 or non-HLA-A2), or allogeneic MCV (mixed HLA-A2 and non-HLA-A2 melanomas).
Results. HLA-A2 MCV and autologous melanoma were similar and significantly better stimulators than the others. Specificity also was supported by CTL killing and mixed lymphocyte tumor reaction assays.
Conclusions. These studies provide important information for the studying immunization of patients with HLA-A2 melanoma with an allogeneic HLA-A2 MCV in a Phase I clinical trial.